StockpollyBeta
Get App
Popularity #1,854
SANA · NASDAQ · Biotechnology

Sana Biotechnology (SANA)

Engineers immune-evading cells and in vivo CAR T therapies for diabetes and B-cell disease.

$3.05
vs last close−0.29 (−8.56%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000020
Gross profit0000000000−20
291111496251519544613565
Research & development−177094334834394033492455
192116161417111010121111
General & administrative192116161417111010121111
Other expenses0000000450000
Operating income−2−91−111−49−62−51−51−95−44−61−38−65
333−1221112−92
Interest income333332111−211
Other non-operating income0−3−31−2−2−1−45−1−29−2
Income before tax1−88−107−50−60−49−49−94−42−59−47−64
Net income from continuing operations1−88−107−50−60−49−49−94−42−59−47−64
Net income1−88−107−50−60−49−49−94−42−59−47−64
EPS, basic$0.01−$0.45−$0.49−$0.21−$0.25−$0.21−$0.21−$0.39−$0.16−$0.21−$0.17−$0.22
EPS, diluted$0.00−$0.45−$0.49−$0.21−$0.25−$0.21−$0.21−$0.39−$0.16−$0.20−$0.17−$0.22
Weighted average shares, basic197197217234235236238238260253277296
Weighted average shares, diluted200197217234235236238238260253277296
EBITDA2−77−104−46−56−43−46−48−39−56−45−61
Depreciation & amortization4114446433322
EBIT−2−88−107−50−60−49−49−50−42−59−47−64